Published in Cancer Res on August 24, 2010
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene (2011) 1.59
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer (2010) 1.38
Regulation of G protein-coupled receptor function by Na+/H+ exchange regulatory factors. Pharmacol Rev (2011) 1.22
NHERF1/EBP50 is a new marker in colorectal cancer. Neoplasia (2010) 1.22
Immunohistochemical analysis of ezrin-radixin-moesin-binding phosphoprotein 50 in prostatic adenocarcinoma. BMC Urol (2011) 0.88
The Role of PTEN in Tumor Angiogenesis. J Oncol (2011) 0.88
Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. Cell Death Dis (2012) 0.85
The scaffolding protein EBP50 promotes vascular smooth muscle cell proliferation and neointima formation by regulating Skp2 and p21(cip1). Arterioscler Thromb Vasc Biol (2011) 0.84
EBP50 regulates the apoptosis of pancreatic cancer cells by decreasing the expression levels of Bcl-2. Exp Ther Med (2014) 0.84
PHLPP2 suppresses the NF-κB pathway by inactivating IKKβ kinase. Oncotarget (2014) 0.83
PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism. Cancer Biol Ther (2015) 0.80
NHERF1/EBP50 is an organizer of polarity structures and a diagnostic marker in ependymoma. Acta Neuropathol Commun (2015) 0.79
Temporal and spatial regulation of ezrin-radixin-moesin-binding phosphoprotein-50-kDa (EBP50) during embryo implantation in mouse uterus. Int J Mol Sci (2012) 0.78
Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance. Oncogene (2017) 0.77
Apical membrane segregation of phosphatidylinositol-4,5-bisphosphate influences parathyroid hormone 1 receptor compartmental signaling and localization via direct regulation of ezrin in LLC-PK1 cells. Cell Signal (2011) 0.77
Roles for NHERF1 and NHERF2 on the regulation of C3a receptor signaling in human mast cells. PLoS One (2012) 0.77
Opening the conformation is a master switch for the dual localization and phosphatase activity of PTEN. Sci Rep (2015) 0.76
The cellular distribution of Na+/H+ exchanger regulatory factor 1 is determined by the PDZ-I domain and regulates the malignant progression of breast cancer. Oncotarget (2016) 0.76
Homeobox genes gain trimethylation of histone H3 lysine 4 in glioblastoma tissue. Biosci Rep (2016) 0.75
NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors. Acta Neuropathol Commun (2016) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36
Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 6.59
The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 5.43
3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol (1998) 5.04
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol (1999) 4.15
PI3K/Akt: getting it right matters. Oncogene (2008) 3.91
Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol (2005) 3.46
The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A (1999) 3.10
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65
A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci U S A (2008) 2.34
PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J (2006) 2.16
EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology (2003) 1.82
Direct association of Bazooka/PAR-3 with the lipid phosphatase PTEN reveals a link between the PAR/aPKC complex and phosphoinositide signaling. Development (2005) 1.79
Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function. Oncogene (2007) 1.54
Roles of NHERF1/EBP50 in cancer. Curr Mol Med (2008) 1.48
NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. Oncogene (2004) 1.44
NHERF-1: modulator of glioblastoma cell migration and invasion. Neoplasia (2009) 1.22
Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro Oncol (2010) 1.00
A model of molecular interactions on short oligonucleotide microarrays. Nat Biotechnol (2003) 9.98
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
NFKBIA deletion in glioblastomas. N Engl J Med (2010) 3.96
Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol (2006) 3.76
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn (2013) 3.36
FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res (2006) 3.28
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res (2005) 3.10
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer (2004) 3.05
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res (2006) 2.70
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev (2011) 2.48
Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 organizes ERM proteins at the apical membrane of polarized epithelia. Proc Natl Acad Sci U S A (2004) 2.31
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J (2006) 2.16
A role for Mer tyrosine kinase in alphavbeta5 integrin-mediated phagocytosis of apoptotic cells. J Cell Sci (2005) 2.15
PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol (2003) 2.14
Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer (2004) 2.11
Three-dimensional tissue culture based on magnetic cell levitation. Nat Nanotechnol (2010) 2.11
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol (2008) 1.94
The Sept4 septin locus is required for sperm terminal differentiation in mice. Dev Cell (2005) 1.92
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res (2006) 1.91
Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg (2010) 1.85
YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res (2005) 1.81
Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc Natl Acad Sci U S A (2007) 1.78
VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol (2008) 1.77
Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia (2010) 1.71
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol (2009) 1.69
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol (2013) 1.63
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res (2009) 1.61
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn (2012) 1.59
Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res (2010) 1.59
Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res (2005) 1.57
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell (2004) 1.57
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev (2013) 1.55
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
NHERF1/EBP50 head-to-tail intramolecular interaction masks association with PDZ domain ligands. Mol Cell Biol (2007) 1.52
Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev (2009) 1.51
Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia (2010) 1.51
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol (2011) 1.50
Roles of NHERF1/EBP50 in cancer. Curr Mol Med (2008) 1.48
The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol (2004) 1.33
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res (2006) 1.30
Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. BMC Med Genomics (2011) 1.29
Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev (2008) 1.28
Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC Genomics (2008) 1.25
Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res (2008) 1.25
Bayesian ensemble methods for survival prediction in gene expression data. Bioinformatics (2010) 1.24
miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer (2010) 1.22
NHERF1/EBP50 is a new marker in colorectal cancer. Neoplasia (2010) 1.22
Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res (2010) 1.21
Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLoS One (2008) 1.17
Aggregation of cancer in first-degree relatives of patients with glioma. Cancer Epidemiol Biomarkers Prev (2007) 1.17
Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol (2014) 1.17
FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res (2010) 1.14
Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res (2007) 1.12
Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst (2005) 1.12
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol (2015) 1.11
Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway. Sci Signal (2009) 1.11
Conversion of myoblasts to physiologically active neuronal phenotype. Genes Dev (2004) 1.11
Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia (2006) 1.10
Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res (2006) 1.08
RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN. Cancer Res (2009) 1.08
Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol (2006) 1.08
Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res (2013) 1.06
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol (2014) 1.06
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res (2013) 1.06
Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res (2007) 1.06
Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy (2008) 1.03
New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res (2012) 1.01
The molecular epidemiology of gliomas in adults. Neurosurg Focus (2005) 1.01
Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest (2010) 1.00
Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro Oncol (2010) 1.00
Moesin is a glioma progression marker that induces proliferation and Wnt/β-catenin pathway activation via interaction with CD44. Cancer Res (2012) 1.00
Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genet Cytogenet (2003) 0.99
Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget (2014) 0.98
Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol (2013) 0.98
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. FEBS Lett (2008) 0.97
αvβ8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion. Mol Biol Cell (2013) 0.97
PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun (2005) 0.97
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol (2006) 0.95
Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res (2011) 0.95
Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma. Brain Pathol (2014) 0.95
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol (2009) 0.94
Biomarkers classification and therapeutic decision-making for malignant gliomas. Curr Treat Options Oncol (2012) 0.93
CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. Am J Pathol (2003) 0.93